In Japan, the cumulative incidence of pancreatic cancer for patients with hereditary pancreatitis bearing the PRSS1 and the serine protease inhibitor Kazal 1 (SPINK1) variants was estimated to be 40% until the age of 70 years17. This evidence concerns the gene SPINK1 and hereditary chronic pancreatitis.